Navigation Links
Duke, LabCorp combine forces to create the Biomarker Factory
Date:4/20/2010

Durham and Burlington, N.C. - Duke University Medical Center and Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today the formation of a joint venture to commercialize new biomarkers. The new entity is designed to speed the translation of newly discovered biomarkers into widely available clinical tools that can measure individual therapeutic responses, predict disease progression, and evaluate any number of biologic or disease-causing processes.

This innovative venture known as The Biomarker Factory combines Duke's excellence in biomarker discovery and validation with LabCorp's expertise in the development and commercialization of innovative diagnostic and laboratory tools.

"The Biomarker Factory is at the intersection of translational medicine and personalized medicine," said Victor J. Dzau, MD, Chancellor for Health Affairs, Duke University, and CEO, Duke University Health System. "By consolidating our collective strengths, this joint venture will be uniquely positioned to accelerate the translation of scientific discoveries into clinical practice, and create the potential for a major step forward in our pursuit of personalized medicine."

"The Biomarker Factory will position Duke and LabCorp on an end-to-end pathway from the research bench to the physician office," said David P. King, Chairman and Chief Executive Officer of LabCorp. "The Biomarker Factory will contribute greatly to the realization of the promise of individualized medicine and will assist physicians in understanding how to use newly developed biomarkers to improve patient outcomes and reduce healthcare costs."

Biomarkers are being used in developing treatments for diseases such as Alzheimer's, heart disease, breast and lung cancer. Recent groundbreaking research by Duke scientists, John McHutchison and David Goldstein demonstrated how biomarkers can give critical information about the likelihood that a patient will benefit from treatment for Hepatitis C.

"Biomarkers give us clues about what to expect about the risk of an illness, its future course and response to treatment, including benefits and harms," commented Rob Califf, MD, Vice Chancellor for Clinical Research at Duke University Medical Center and Director of the Duke Translational Medicine Institute.

"A particularly exciting aspect of this partnership is that we will be developing deep knowledge about appropriate use of biomarkers in clinical practice and how to provide this information so that patients and doctors can make better decisions," added Andrew Conrad, Ph.D., Executive Vice President and Chief Scientific Officer of LabCorp.

The Biomarker Factory will benefit from hundreds of thousands of biological samples contributed by Duke, as well as the infrastructure already in place in the Duke-led, large-scale epidemiology study known as MURDOCK, which is currently recruiting 50,000 people into a registry. The Biomarker Factory will also capitalize on LabCorp's biorepository being developed to discover and validate biomarkers in human disease. Financial terms were not disclosed.

"The Biomarker Factory will leverage existing assets in both founding organizations and focus them in a new way to rigorously demonstrate the utility of biomarkers to stratify disease, conserve healthcare resources, and optimize health outcomes," says Victoria Christian, Chief Operating Officer of the Duke Translational Research Institute who spearheaded the enterprise.


'/>"/>

Contact: Debbe Geiger
Debbe.Geiger@duke.edu
919-660-9461
Duke University Medical Center
Source:Eurekalert

Related biology news :

1. Duke, Harvard researchers to monitor bonobo reintroduction
2. Extended wakefulness, combined with alcohol, severely impairs driving performance
3. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
4. Fujitsu Combines Capacity, Performance and Power Efficiency Into the Industrys First 320GB 7200 RPM 2.5" Sata Hard Disk Drive
5. Bee species outnumber mammals and birds combined
6. Sociological research shows combined impact of genetics, social factors on delinquency
7. Smothered genes combine with mutations to yield poor outcome in cancer patients
8. Pictometry and First American Combine Accurate Parcel Addressing With 3-D Like Intelligent Images(TM)
9. New research center at Brandeis to combine materials science and biology
10. A combined tooth-venom arsenal revealed as key to Komodo dragons hunting strategy
11. Combined stem cell-gene therapy approach cures human genetic disease in vitro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
(Date:1/20/2016)... A market that just keeps on growing. Molecular Diagnostics ... genomics knowledge. Learn all about it in this new ... trends are pushing market growth and company valuations. Trends ... pathogen evolution - next generation sequencing - emergence of ... the role of genetic material in Disease and Health ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) to distribute exosome injection and other biological products ... Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, ...
(Date:2/10/2016)... Feb. 10, 2016 NX Prenatal Inc., a ... NeXosome® technology for early warning of adverse pregnancy ... recent study by Dr. Thomas McElrath ... Maternal Fetal Medicine,s (SMFM) annual meeting held in ... , 2016.  The presentation reported initial positive top-line ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., a ... fast growing biotech companies, announced today the appointment ... Strategic Advisor. Jim brings nearly 25 years of ... procurement, having spent nearly two decades in executive ... and Procurement at Genzyme and, most recently headed ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, ... 2014. More than 1,600 participants have joined the PROMPT study, which seeks to ...
Breaking Biology Technology: